Audrey Mailliez - Department of General Oncology, Centre Oscar LambretLilleFrance

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 193 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Prognosis and Clinicopathological Characteristics of HER2-negative Metastatic Breast Cancers with Low Expression of Hormone Receptors: Real World Evidence from the French ESME Cohort

Marie Alexandre, Ludovic Gauthier,Audrey Mailliez, Thibault De La Motte Rouge, Thomas Bachelot,Monica Arnedos,Florence Dalenc,Etienne Brain, Jean-Marc Ferrero,Vincent Massard,Isabelle Desmoulins, Marie-Ange Mouret-Reynier,Christelle Levy,Anthony Goncalves, Marianne Leheurteur, Thierry Petit, Jean-Sebastien Frenel, Lise Bosquet,Suzette Delaloge, William Jacot

CANCER RESEARCHno. 9 (2024)

Cited0Views0Bibtex

Breast Cancer Prognosis in Young BRCA1/BRCA2 Mutation Carriers: a Retrospective Hospital-Based Cohort Study

Florent Hego, Maël Barthoulot, Sebastian Chretien, Charles Pierard, Manon Boulaire, Stéphanie Bécourt, Loïc Boulanger,Luc Ceugnart, Anne Laure Conoy, Florine Oca,Audrey Mailliez

Clinical Oncology (2024)

Cited0Views0Bibtex

1003P A First-in-human (FIH) Phase I Study of IPH5301, an Anti-Cd73 Monoclonal Antibody (mab), in Patients with Advanced Solid Tumors (AST) (CHANCES, NCT05143970)

M. Beaufils,A. Mailliez,P. Sfumato,C. Vicier,M. Provansal Gross, M. Guerin, B. Chanez,N. Kotecki, A. Widemann, S. Panzolato,A. Boyer Chammard, P. André,C.L. Paturel, C. Gouarne, A.H. Awada,J.M. Boher, A. Gonçalves

Annals of Oncology (2024)

Cited0Views0Bibtex

Therapeutic Impact of 18F-FDG PET/CT for Initial Staging in Patients with Clinical Stage I and IIA, HER2-positive, or Triple-Negative Breast Cancer

Chloé François,Audrey Mailliez,Sebastian Chretien,Clémence Leguillette,Aurore Oudoux,Luc Ceugnart,Maël Barthoulot,Olivier Cougnenc, Anaïs Olivier

BREAST CANCER RESEARCH AND TREATMENT (2024)

Cited0Views0WOSBibtex

124P Neoadjuvant Durvalumab Plus Endocrine Therapy Following Immune-Attractant Exposure for Early-Stage ER+/HER2- Breast Cancer

B. Verret,M. Lacroix-Triki,S. Ladoire,F. Dalenc,S. Giacchetti,E.G.C. Brain,T. Bachelot,H. Vegas,A. Zannetti,M-A. Mouret-Reynier, R. Lamy,N. Quenel Tueux,L. Venat-Bouvet,A. Mailliez,S. Morales Murillo, D.A. Cameron,S. Michiels,J. Lemonnier, A. Prat, F. André

ESMO Open (2024)

Cited0Views0Bibtex

P23 - Evolution Des Traitements De Première Ligne Et Survie En Vie Réelle Des Femmes Âgées Atteintes D'un Cancer Du Sein Métastatique RH+/HER2- Par Rapport Aux Femmes Plus Jeunes : Résultats De L’étude Observationnelle Et Nationale ESME

F. Bouteiller,C. Courtinard, S. Gourgou,A. Galvin, F. Dalenc,A. Mailliez,M. Bringuier, S. Delaloge, C. Bellera

Journal of Epidemiology and Population Health (2024)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn